The ACR/CHEST ILD Guidelines in Practice: Register Now for This Informative Webinar

An official publication of the ACR and the ARP serving rheumatologists and rheumatology professionals

Search results for: hospital

Adventist Health System to Pay $118 Million to Settle Fraud Claims

Brendan Pierson  |  

(Reuters)—Florida-based healthcare system Adventist Health System has agreed to pay $118.7 million to settle a whistleblower lawsuit that accused it of paying kickbacks to doctors in exchange for referrals, attorneys for the plaintiffs announced on Monday. The agreement comes in a lawsuit filed by three former employees of Adventist’s Park Ridge Health hospital in Hendersonville,…

Reforms Needed to Address Medical Diagnostic Errors

Julie Steenhuysen  |  

CHICAGO (Reuters)—Most Americans will fall victim to at least one diagnostic error in their lifetime, and when this occurs, it often can be deadly, according to a new report released on Tuesday by the Institute of Medicine, which advises the U.S. government and policymakers. The report called for greater emphasis on improving diagnoses in the…

Chronic Care Management Payments Can Increase Primary Care Revenues

Will Boggs, MD  |  

NEW YORK (Reuters Health)—Medicare’s new chronic care management (CCM) payments could boost revenues for primary care practices, but many could experience net losses due to opportunity costs of face-to-face visit time, according to results from a modeling study. “The loss of revenue when MD’s did all the work themselves was somewhat surprising,” Dr. Sanjay Basu,…

Methotrexate Halt Feasible in Some Etanercept RA Responders

David Douglas  |  

NEW YORK (Reuters Health)—Certain rheumatoid arthritis (RA) patients doing well on etanercept and methotrexate may be able to quit the latter agent if they have tolerability problems, according to an open-label Canadian study. In a Sept. 11 online paper in Rheumatology, Dr. Boulos Haraoui, of the University of Montreal, and colleagues noted that although combination…

New Labeling for Infused Golimumab; Phase 3 Trial for Romosozumab Promising

  |  

The FDA has approved new labeling for infused golimumab to include measures of mental and physical health. Plus romosozumab meets primary endpoints in postmenopausal women with osteoporosis during a Phase 3 trial…

Figure 1: Hematoxylin & Eosin Staining

Systemic Lupus Erythematosus Without Kidney Involvement: A Case Report

Paul Hoover, MD, PhD, & Lindsey MacFarlane, MD  |  

A 35-year-old female with a history of systemic lupus erythematosus (SLE) without kidney involvement was admitted to our hospital with low-grade fevers, headache, increasing lower extremity edema and elevated blood pressure. History She was first diagnosed with SLE as a teenager when she developed oral ulcers and pleuritic chest pain and tested positive for anti-Smith…

Rheumatologists on the Move, September 2015

  |  

Teresa Fama: Rheumatologist to Chair Public Advisory Council Teresa Fama, MD, is the new chair of the New England Comparative Effectiveness Public Advisory Council (CEPAC). A rheumatologist who practices in Berlin, Vt., Dr. Fama has previous experience in public policy, specifically health policy. Before she began her second career as a physician, Dr. Fama was…

Vitamin D in Rheumatology: Cause and Effect Unclear

  |  

The controversy over vitamin D is hearty enough to confuse even seasoned rheumatologists, says Nathan Wei, MD, The Arthritis Treatment Center, Frederick, Md. “It’s like what you hear with coffee. One week, [a study finds] coffee is … good for you; the next week, there’s a study saying it’s bad for you,” he says. Vitamin…

Preparing Immunocompromised Patients for Risks of Traveling Abroad

  |  

Summer is a season for travel, so if your immunocompromised patients plan to journey to regions where there are outbreaks of infections, such as chikungunya, tuberculosis, typhoid, yellow fever or other diseases, communication and preparation may prevent serious health events. “The world teems with disease-causing organisms, and almost every infection is more serious in the…

Fellow’s Forum Case Report: Limited Cutaneous Systemic Sclerosis

Eunjung Kim, MD, Hyun Bae, MD, Ritu Kathuria, MD, Alexandra Gottdiener, MD, & Girish Sonpal, MD, FACR  |  

Systemic sclerosis (SSc) is an acquired, sporadic, autoimmune, connective tissue disease with two subsets: limited cutaneous scleroderma (lcSSc) and diffuse cutaneous scleroderma (dcSSc). In the U.S., the annual incidence is about 20 cases per 1 million adults, with a prevalence of about 240 cases per 1 million adults.1 As with other connective tissue disorders, SSc…